AstraZeneca Caps US Inhaler Costs at $35/month

AstraZeneca will limit out-of-pocket costs for inhalers and related medication to $35 per month starting June 1, aiming to assist uninsured patients with asthma or chronic obstructive pulmonary disease. This move follows pressure from lawmakers and a similar initiative by Boehringer Ingelheim, but GlaxoSmithKline and Teva have not committed to a price cap. The Asthma and Allergy Foundation of America supports efforts to make asthma drugs more affordable and urges all healthcare industry stakeholders to collaborate in reducing costs.